Product Name :
B-HT 920
Description:
Talipexole, also known as B-HT920 and Domnin, is a dopamine agonist that is marketed as a treatment for Parkinson’s Disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe. Talipexole is a D2 dopamine receptor agonist and interacts both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist. The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints. In 2008 the Japanese Ministry of Health, Labour, and Welfare mandated that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.
CAS:
36085-73-1
Molecular Weight:
282.{{Probucol} site|{Probucol} Anti-infection|{Probucol} Biological Activity|{Probucol} Data Sheet|{Probucol} supplier|{Probucol} Cancer} 23
Formula:
C10H17Cl2N3S
Chemical Name:
6-(prop-2-en-1-yl)-4H,5H,6H,7H,8H-[1,3]thiazolo[4,5-d]azepin-2-amine dihydrochloride
Smiles :
Cl.Cl.C=CCN1CCC2SC(N)=NC=2CC1
InChiKey:
DPQAXNSOFFYKDS-UHFFFAOYSA-N
InChi :
InChI=1S/C10H15N3S.2ClH/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8;;/h2H,1,3-7H2,(H2,11,12);2*1H
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥360 days if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Talipexole, also known as B-HT920 and Domnin, is a dopamine agonist that is marketed as a treatment for Parkinson’s Disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe. Talipexole is a D2 dopamine receptor agonist and interacts both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist. The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints. In 2008 the Japanese Ministry of Health, Labour, and Welfare mandated that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.{{Fianlimab} MedChemExpress|{Fianlimab} Immunology/Inflammation|{Fianlimab} Technical Information|{Fianlimab} Purity|{Fianlimab} manufacturer|{Fianlimab} Autophagy} |Product information|CAS Number: 36085-73-1|Molecular Weight: 282.PMID:24211511 23|Formula: C10H17Cl2N3S|Chemical Name: 6-(prop-2-en-1-yl)-4H,5H,6H,7H,8H-[1,3]thiazolo[4,5-d]azepin-2-amine dihydrochloride|Smiles: Cl.Cl.C=CCN1CCC2SC(N)=NC=2CC1|InChiKey: DPQAXNSOFFYKDS-UHFFFAOYSA-N|InChi: InChI=1S/C10H15N3S.2ClH/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8;;/h2H,1,3-7H2,(H2,11,12);2*1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|